Abstract:Kuo-Tung Hung, 1 Shih-Cheng Yang, 1 Cheng-Kun Wu, 1, 2 Hsing-Ming Wang, 1 Chih-Chien Yao, 1 Chih-Ming Liang, 1, 2 Wei-Chen Tai, 1, 2 Keng-Liang Wu, 1, 2 Yuan-Hung Kuo, 1, 2 Chen-Hsiang Lee, 2, 3 Seng-Kee Chuah 1, 2 1 Division of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 2 Chang Gung University, College of Medicine, Taoyuan, Taiwan; 3 Division of Infectious Disease, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan Correspondence: Seng-Kee Chuah; Chih-Ming Liang Division of Hepatogastroenterology, Chang Gung Memorial Hospital, 123, Ta-Pei Road, Niao-Sung Hsiang, Kaohsiung, 833, Taiwan Tel + 886-7-7317123 ext. 8301 Fax + 886-7-7322402 Email chuahsk@seed.net.tw; gimy54861439@gmail.com Purpose: Non-bismuth concomitant quadruple therapy is commonly administered in Taiwan, achieving an acceptable efficacy as a first-line anti -Helicobacter pylori treatment. This study compared the eradication rates between esomeprazole- and lansoprazole-based non-bismuth concomitant quadruple therapy for first-line anti- H. pylori treatment. Patients and Methods: This study included 206 H. pylori -infected naïve patients between July 2016 and February 2019. The patients were prescribed with either a 7-day non-bismuth containing quadruple therapy (esomeprazole, 40 mg twice daily; amoxicillin, 1 g twice daily; and metronidazole, 500 mg twice daily; and clarithromycin, 500 mg twice daily for 7 days [EACM group]; lansoprazole, 30 mg twice daily; amoxicillin, 1 g twice daily; metronidazole, 500 mg twice daily; and clarithromycin, 500 mg twice daily [LACM group]). Then, the patients were asked to perform urea breath tests 8 weeks later. Results: The eradication rates in the EACM group were 86.1% (95% confidence interval [CI], 77.8%– 92.2%) and 90.6% (95% CI, 82.9%– 95.6%) in the intention-to-treat (ITT) and the per-protocol (PP) analyses, respectively. Moreover, the eradication rates in the LACM group were 90.1% (95% CI, 82.6%– 95.2%) and 92.6% (95% CI, 85.5%– 96.9%) in the ITT and the PP analyses, respectively. Consequently, the LACM group exhibited more diarrhea patients than the EACM group (7.1% versus 1.0%, p = 0.029), but all symptoms were mild. Univariate analysis in this study showed that metronidazole-resistant strains were the clinical factor affecting the eradications (95.3% versus 78.9%, p = 0.044). Moreover, a trend was observed in dual clarithromycin- and metronidazole-resistant strains (91.5% versus 66.7%, p = 0.155). Conclusion: The eradication rates between esomeprazole and lansoprazole-based non-bismuth concomitant quadruple therapy for first-line H. pylori treatment were similar in this study. Both could achieve a > 90% report card in the PP analysis. Keywords: Helicobacter pylori , esomeprazole, lansoprazole, concomitant therapy, antibiotic resistance

The short and long term effect of exomeprazole-based triple therapy curing duodenal ulcer of Helicobacter pylori infection

Long-term Therapeutic Effect of Triple Therapy Consisted of Omeperazole,clarithromycin and Amoxycillin in Children with Helicobacter Pylori Infection and Approach to Re-Treatment after Failure of the Treatment

Effieacy of rabeprazole in freating patients with duodenal ulcer and its effect gastric parietal cell density

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Short-term Outcomes and Intermediate-Term Follow-Up of Helicobacter Pylori Infection Treatment for Naïve Patients: a Retrospective Observational Study.

Quadruple Therapy with Vonoprazan 20 Mg Daily As a First-Line Treatment for Helicobacter Pylori Infection: A Single-Center, Open-Label, Noninferiority, Randomized Controlled Trial.

Meta-analysis of Esomeprazole-Based Triple Therapies in Helicobacter Pylori Eradication

Effect of Helicobacter pylori eradication on reflux esophagitis therapy: a multi-center randomized control study.

Therapeutic Effect of Triple Therapy Combined with Posture Change after Taking Medicine for Helicobacter pylori Eradication in Remnant Stomach

Efficacy of Tetracycline-containing Triple Therapy for Eradication of Helicobacter pylori Infection

Serum Antibodies of Helicobacter Pylori Affecting Eradication Efficacy of Esomeprazole Quadruple Therapy

Clinical Impact of High-dose Esomeprazole-amoxicillin Dual Therapy As Rescue Treatment for Helicobacter Pylori Infection

Efficacy of Triple Therapy and Sequential Therapy in the Eradication of Helicobacter Pylori in Patients Receiving Long-Term Non-Steroidal Anti-Inflammatory Drugs Treatment

Comparison of Two Low_dose Short_term Triple Therapies for Eradication of Helicobacter Pylori Infection

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice

Comparison of efficacy of different treatment regimens on H.Pylori Eradication

Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis

Pharmacogenetics of Esomeprazole or Rabeprazole-Based Triple Therapy in Helicobacter Pylori Eradication in Hong Kong Non-Ulcer Dyspepsia Chinese Subjects

Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori infection: a multicenter, randomized controlled clinical trial

A Comparative Study of 14‐day Dual Therapy (esomeprazole and Amoxicillin Four Times Daily) and Triple Plus Bismuth Therapy for First‐line Helicobacter Pylori Infection Eradication: A Randomized Trial

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori